Peter Melnyk Takes the Helm as President and CEO of Taiho Oncology

Princeton, NJ, January 28, 2026 (Business Wire) -- Taiho Oncology appointed Peter Melnyk as President and Chief Executive Officer, effective immediately, following the retirement of Tim Whitten after 13 years of leadership. Melnyk brings more than three decades of experience in oncology commercialization across pharma, biotech, and medical devices, most recently serving as Chief Commercial Officer at Alpha Tau Medical. His appointment comes as Taiho Oncology builds on recent commercial growth, having expanded from a single product to three marketed therapies across five indications, alongside a growing oncology pipeline.

Read full article here.